Search

Your search keyword '"Lombard-Bohas, C"' showing total 415 results
Start Over Author "Lombard-Bohas, C"
415 results on '"Lombard-Bohas, C"'

3. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

4. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

Author

Stephanie, Laetitia, Borbath, Ivan, Castex, Petorin, Caroline, Terrebonne, Eric, Bouhier-Leporrier, Karine, Suc, Etienne, Hautefeuille, Vincent, Bourgeois, Vincent, Cany, Laurent, Dewaele, François, Niccoli, Patricia, Seitz, Jean-François, Lecaille, Cédric, Rebischung, Christine, Rossi, Valérie, Baconnier, Mathieu, Dubreuil, Olivier, Ferec, Marc, Deplanque, Gael, Geslin, Guillaume, Wanicki Caron, Isabelle, Lavau Denes, Sandrine, Bedenne, Laurent, Ligeza, Catherine, Maringe, Eric, Ran-Royo, Anne-Laure, Guigay, Joel, Rougier, Philippe, Walter, T., Tougeron, D., Baudin, E., Le Malicot, K., Lecomte, T., Malka, D., Hentic, O., Manfredi, S., Bonnet, I., Guimbaud, R., Coriat, R., Lepère, C., Desauw, C., Thirot-Bidault, A., Dahan, L., Roquin, G., Aparicio, T., Legoux, J.-L., Lombard-Bohas, C., Scoazec, J.-Y., Lepage, C., and Cadiot, G.

Published
2017
Full Text
View/download PDF

5. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Author

Kulke, M.H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J.W., De Herder, W.W., Pavel, M., Degtyarev, E., Brase, J.C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R.P., and Yao, J.C.

Published
2017
Full Text
View/download PDF

7. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, Spada, Francesca, Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, and Spada, Francesca

Abstract

We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.

Published
2023

9. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

Author

Aparicio, T., Lavau-Denes, S., Phelip, J.M., Maillard, E., Jouve, J.L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., Khemissa, F., Lecomte, T., Provençal, J., Breysacher, G., Legoux, J.L., Lepère, C., Charneau, J., Cretin, J., Chone, L., Azzedine, A., Bouché, O., Sobhani, I., Bedenne, L., Mitry, E., Amoyal, P., Auby, D., Bachet, J.B., Baconnier, M., Benoit, R., Berthelet, O., Bidault, A., Bineau, C., Bordes, G., Bouarioua, N., Boucher, E., Boulat, O., Cleau, D., Couzigou, P., Cuillerier, E., Cumin, I., Denis, B., Di Fiore, F., Derias, V., Ezenfis, J., Faroux, R., Gagnaire, A., Gatineau-Sailliant, G., Garcia, B., Genet, D., Gueye, A., Hammel, P., Lagasse, J.P., Landi, B., Lepage, C., Lobry, C., Lombard-Bohas, C., Mabro, M., Mackiewicz, R., Martin, J., Moncoucy, X., Morvan, F., Mozer, M., Pauwels, M., Petit-Laurent, F., Pouderoux, P., Prost, P., Queuniet, A.M., Ramdani, M., Rebischung, C., Rougier, P., Schnee, M., Seitz, J.F., Stefani, L., Taïeb, J., Terrebonne, E., Texereau, P., Thaury, J., Tougeron, D., Weber, A., Ricard, F., Bonnetain, F., Masskouri, F., Choine, C., Guiliani, F., Le Pessec, G., Fattouh, H., Le Provost, N., Girault, C., and Schneider, M.

Published
2016
Full Text
View/download PDF

11. Comment différencier un ‘vrai’ d’un ‘faux’ VIPome : étude nationale multicentrique du GTE-ENDOCAN-RENATEN avec test d’interférence biologique

Author

Chevalier, B., primary, Bonnet, D., additional, Lepage, C., additional, Cadiot, G., additional, Borson Chazot, F., additional, Abeillon, J., additional, Delobel, J.B., additional, Jannin, A., additional, Haissaguere, M., additional, Lombard-Bohas, C., additional, Walter, T., additional, and Chardon, L., additional

Published
2022
Full Text
View/download PDF

12. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

Author

Baudin, E., primary, Walter, T.A., additional, Beron, A., additional, Smith, D., additional, Hadoux, J., additional, Lachachi, C., additional, Taieb, D., additional, Ansquer, C., additional, Dierickx, L.O., additional, de Mestier du Bourg, L., additional, Deshayes, E., additional, Quak, E., additional, Dahan, L., additional, Guimbaud, R., additional, Touchefeu, Y., additional, Haissaguerre, M., additional, Do Cao, C., additional, Lombard Bohas, C., additional, Attard, M., additional, and Foulon, S., additional

Published
2022
Full Text
View/download PDF

15. Corrigendum to “Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Author

Baudin, E., primary, Caplin, M., additional, Garcia-Carbonero, R., additional, Fazio, N., additional, Ferolla, P., additional, Filosso, P.L., additional, Frilling, A., additional, de Herder, W.W., additional, Hörsch, D., additional, Knigge, U., additional, Korse, C.M., additional, Lim, E., additional, Lombard-Bohas, C., additional, Pavel, M., additional, Scoazec, J.Y., additional, Sundin, A., additional, and Berruti, A., additional

Published
2021
Full Text
View/download PDF

19. LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Author

Walter, T., Lecomte, T., Hadoux, J., Niccoli, P., Saban-Roche, L., Gaye, E., Guimbaud, R., Baconnier, M., Hautefeuille, V., Do Cao, C., Petorin, C., Hentic Dhome, O., Perrier, M., Aparicio, T., Scoazec, J-Y., Lombard Bohas, C., Bin, S., Hervieu, V., Barritault, M., and Gerard, L.

Published
2023
Full Text
View/download PDF

23. Expression of (beta)-catenin in gastroenteropancreatic endocrine tumours: a study of 229 cases

Author

Hervieu, V., Lepinasse, F., Gouysse, G., Guillaud, O., Barel, C., Chambonniere, M.-L., Bringuier, P.-P., Poncet, G., Lombard-Bohas, C., Partensky, C., Chayvialle, J.-A., and Scoazec, J.-Y.

Subjects
Gene expression -- Case studies, Endocrine gland diseases -- Research, Endocrine gland diseases -- Diagnosis, Tumors -- Case studies, Tumors -- Diagnosis, Immunohistochemistry -- Evaluation, Health
Published
2006

34. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Author

Kulke, M.H., primary, Ruszniewski, P., additional, Van Cutsem, E., additional, Lombard-Bohas, C., additional, Valle, J.W., additional, De Herder, W.W., additional, Pavel, M., additional, Degtyarev, E., additional, Brase, J.C., additional, Bubuteishvili-Pacaud, L., additional, Voi, M., additional, Salazar, R., additional, Borbath, I., additional, Fazio, N., additional, Smith, D., additional, Capdevila, J., additional, Riechelmann, R.P., additional, and Yao, J.C., additional

Published
2019
Full Text
View/download PDF

35. Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen

Author

Ruszniewski, P., primary, Ćwikła, J., additional, Lombard-Bohas, C., additional, Borbath, I., additional, Shah, T., additional, Pape, U.-F., additional, Truong Thanh, X.-M., additional, Houchard, A., additional, and Pavel, M.E., additional

Published
2019
Full Text
View/download PDF

36. Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French group of endocrine tumours (GTE)

Author

Dekeister Geoffroy, K., primary, Francois, L., additional, Walter, T., additional, Hentic Dhome, O., additional, Cachier, A., additional, Cadiot, G., additional, Nazeyrollas, P., additional, Afchain, P., additional, Ederhy, S., additional, Lepage, C., additional, Eicher, J.-C., additional, Coriat, R., additional, Cabanes, L., additional, Baudin, E., additional, Dominguez, S., additional, Delelis, F., additional, Forestier, J., additional, and Lombard Bohas, C., additional

Published
2019
Full Text
View/download PDF

38. Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: The FFCD 1104-EVACEL-GTE phase II study

Author

Walter, T., primary, Lepage, C., additional, Coriat, R., additional, Barbier, E., additional, Cadiot, G., additional, Caroli Bosc, F.X., additional, Aparicio, T., additional, Bouhier Leporrier, K., additional, Hentic Dhome, O., additional, Dupont-Gossart, A.-C., additional, Duluc, M., additional, Lepere, C., additional, Lecomte, T., additional, Smith, D., additional, Petorin, C., additional, Iwanicki Caron, I., additional, Ducreux, M.P., additional, Lombard Bohas, C., additional, and de Baere, T., additional

Published
2018
Full Text
View/download PDF

40. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Aparicio, Thomas, primary, Ducreux, Michel, additional, Faroux, Roger, additional, Barbier, Emilie, additional, Manfredi, Sylvain, additional, Lecomte, Thierry, additional, Etienne, Pierre-Luc, additional, Bedenne, Laurent, additional, Bennouna, Jaafar, additional, Phelip, Jean-Marc, additional, François, Eric, additional, Michel, Pierre, additional, Legoux, Jean-Louis, additional, Gasmi, Mohamed, additional, Breysacher, Gilles, additional, Rougier, Philippe, additional, De Gramont, Aimery, additional, Lepage, Come, additional, Bouché, Olivier, additional, Seitz, Jean-François, additional, Adenis, A., additional, Alessio, A., additional, Aouakli, A., additional, Azzedine, A., additional, Bedjaoui, A., additional, Bidault, A., additional, Blanchi, A., additional, Botton, A., additional, Cadier-Lagnes, A., additional, Fatisse, A., additional, Gagnaire, A., additional, Gilbert, A., additional, Gueye, A., additional, Hollebecque, A., additional, Lemaire, A., additional, Mahamat, A., additional, Marre, A., additional, Patenotte, A., additional, Rotenberg, A., additional, Roussel, A., additional, Thirot-Bidault, A., additional, Votte, A., additional, Weber, A., additional, Zaanan, A., additional, Dupont-Gossart, A.C., additional, Villing, A.L., additional, Queuniet, A.M., additional, Coudert, B., additional, Denis, B., additional, Garcia, B., additional, Lafforgue, B., additional, Landi, B., additional, Leduc, B., additional, Linot, B., additional, Paillot, B., additional, Rhein, B., additional, Winkfield, B., additional, Barberis, C., additional, Becht, C., additional, Belletier, C., additional, Berger, C., additional, Bineau, C., additional, Borel, C., additional, Brezault, C., additional, Buffet, C., additional, Cornila, C., additional, Couffon, C., additional, De La Fouchardière, C., additional, Giraud, C., additional, Lecaille, C., additional, Lepere, C., additional, Lobry, C., additional, Locher, C., additional, Lombard-Bohas, C., additional, Paoletti, C., additional, Platini, C., additional, Rebischung, C., additional, Sarda, C., additional, Vilain, C., additional, Briac-Levaché, C., additional, Auby, D., additional, Baudet-Klepping, D., additional, Bechade, D., additional, Besson, D., additional, Cleau, D., additional, Festin, D., additional, Gargot, D., additional, Genet, D., additional, Goldfain, D., additional, Luet, D., additional, Malka, D., additional, Peré-Vergé, D., additional, Pillon, D., additional, Sevin-Robiche, D., additional, Smith, D., additional, Soubrane, D., additional, Tougeron, D., additional, Zylberait, D., additional, Carola, E., additional, Cuillerier, E., additional, Dorval Danquechin, E., additional, Echinard, E., additional, Janssen, E., additional, Maillard, E., additional, Mitry, E., additional, Norguet-Monnereau, E., additional, Suc, E., additional, Terrebonne, E., additional, Zrihen, E., additional, Pariente, E.A., additional, Almaric, F., additional, Audemar, F., additional, Bonnetain, F., additional, Desseigne, F., additional, Dewaele, F., additional, Di Fiore, F., additional, Ghiringhelli, F., additional, Husseini, F., additional, Khemissa, F., additional, Kikolski, F., additional, Morvan, F., additional, Petit-Laurent, F., additional, Riot, F., additional, Subtil, F., additional, Zerouala-Boussaha, F., additional, Caroli-Bosc, F.X., additional, Boilleau-Jolimoy, G., additional, Bordes, G., additional, Cavaglione, G., additional, Coulanjon, G., additional, Deplanque, G., additional, Gatineau-Saillant, G., additional, Goujon, G., additional, Medinger, G., additional, Roquin, G., additional, Brixi-Benmansour, H., additional, Castanie, H., additional, Lacroix, H., additional, Maechel, H., additional, Perrier, H., additional, Salloum, H., additional, Senellart, H., additional, Baumgaertner, I., additional, Cumin, I., additional, Graber, I., additional, Trouilloud, I., additional, Boutin, J., additional, Butel, J., additional, Charneau, J., additional, Cretin, J., additional, Dauba, J., additional, Deguiral, J., additional, Egreteau, J., additional, Ezenfis, J., additional, Forestier, J., additional, Goineau, J., additional, Lacourt, J., additional, Lafon, J., additional, Martin, J., additional, Meunier, J., additional, Moreau, J., additional, Provencal, J., additional, Taieb, J., additional, Thaury, J., additional, Tuaillon, J., additional, Vergniol, J., additional, Villand, J., additional, Vincent, J., additional, Volet, J., additional, Bachet, J.B., additional, Barbare, J.C., additional, Souquet, J.C., additional, Grangé, J.D., additional, Dor, J.F., additional, Paitel, J.F., additional, Jouve, J.L., additional, Raoul, J.L., additional, Cheula, J.M., additional, Gornet, J.M., additional, Sabate, J.M., additional, Vantelon, J.M., additional, Vaillant, J.N., additional, Aucouturier, J.P., additional, Barbieux, J.P., additional, Herr, J.P., additional, Lafargue, J.P., additional, Lagasse, J.P., additional, Latrive, J.P., additional, Plachot, J.P., additional, Ramain, J.P., additional, Robin, J.P., additional, Spano, J.P., additional, Douillard, J.Y., additional, Beerblock, K., additional, Bouhier-Leporrier, K., additional, Slimane Fawzi, K., additional, Cany, L., additional, Chone, L., additional, Dahan, L., additional, Gasnault, L., additional, Rob, L., additional, Stefani, L., additional, Wander, L., additional, Baconnier, M., additional, Ben Abdelghani, M., additional, Benchalal, M., additional, Blasquez, M., additional, Carreiro, M., additional, Charbit, M., additional, Combe, M., additional, Duluc, M., additional, Fayolle, M., additional, Gignoux, M., additional, Giovannini, M., additional, Glikmanas, M., additional, Mabro, M., additional, Mignot, M., additional, Mornet, M., additional, Mousseau, M., additional, Mozer, M., additional, Pauwels, M., additional, Pelletier, M., additional, Porneuf, M., additional, Ramdani, M., additional, Schnee, M., additional, Tissot, M., additional, Zawadi, M., additional, Clavero-Fabri, M.C., additional, Gouttebel, M.C., additional, Kaminsky, M.C., additional, Galais, M.P., additional, Abdelli, N., additional, Barrière, N., additional, Bouaria, N., additional, Bouarioua, N., additional, Delas, N., additional, Gérardin, N., additional, Hess-Laurens, N., additional, Stremsdoerfer, N., additional, Berthelet, O., additional, Boulat, O., additional, Capitain, O., additional, Favre, O., additional, Amoyal, P., additional, Bergerault, P., additional, Burtin, P., additional, Cassan, P., additional, Chatrenet, P., additional, Chiappa, P., additional, Claudé, P., additional, Couzigou, P., additional, Feydy, P., additional, Follana, P., additional, Geoffroy, P., additional, Godeau, P., additional, Hammel, P., additional, Laplaige, P., additional, Lehair, P., additional, Martin, P., additional, Novello, P., additional, Pantioni, P., additional, Pienkowski, P., additional, Pouderoux, P., additional, Prost, P., additional, Ruszniewski, P., additional, Souillac, P., additional, Texereau, P., additional, Thévenet, P., additional, Haineaux, P.A., additional, Benoit, R., additional, Coriat, R., additional, Lamy, R., additional, Mackiewicz, R., additional, Beorchia, S., additional, Chaussade, S., additional, Hiret, S., additional, Jacquot, S., additional, Lavau Denes, S., additional, Montembault, S., additional, Nahon, S., additional, Nasca, S., additional, Nguyen, S., additional, Oddou-Lagraniere, S., additional, Pesque-Penaud, S., additional, Fratte, S.P., additional, Chatellier, T., additional, Mansourbakht, T., additional, Morin, T., additional, Walter, T., additional, Boige, V., additional, Bourgeois, V., additional, Derias, V., additional, Guérin-Meyer, V., additional, Hautefeuille, V., additional, Jestin Le Tallec, V., additional, Lorgis, V., additional, Quentin, V., additional, Sebbagh, V., additional, Veuillez, V., additional, Adhoute, X., additional, Coulaud, X., additional, Becouarn, Y., additional, Coscas, Y., additional, Courouble, Y., additional, Le Bricquir, Y., additional, Molin, Y., additional, Rinaldi, Y., additional, Lam, Y.H., additional, and Ladhib, Z., additional

Published
2018
Full Text
View/download PDF

41. Étude OPALINE – étude observationnelle en vie réelle, des traitements systémiques des tumeurs neuroendocrines du pancréas (TNEp) non résécables ou métastatiques bien différenciées progressives

Author

Vicaut, E., primary, Smith, D., additional, Lombard-Bohas, C., additional, Dominguez, S., additional, Coriat, R., additional, Goichot, B., additional, Dubreuil, O., additional, Lecomte, T., additional, Santos, A., additional, Borie, O., additional, and Lepage, C., additional

Published
2018
Full Text
View/download PDF

42. Impact of Concomitant Medication on Efficacy of Telotristat Ethyl - A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

Author

Anthony, L., Kulke, M. H., Hoersch, D., Bergsland, E., Öberg, Kjell, Welin, Staffan, Lombard-Bohas, C., Kunz, P., Valle, J. W., Kassler-Taub, K., Fleming, R., Pavel, M., Anthony, L., Kulke, M. H., Hoersch, D., Bergsland, E., Öberg, Kjell, Welin, Staffan, Lombard-Bohas, C., Kunz, P., Valle, J. W., Kassler-Taub, K., Fleming, R., and Pavel, M.

Abstract

Meeting Abstract: L2

Published
2017

43. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Walter, T, Tougeron, D, Baudin, E, Le Malicot, K, Lecomte, T, Malka, D, Hentic, O, Manfredi, S, Bonnet, I, Guimbaud, R, Coriat, R, Lepère, C, Desauw, C, Thirot-Bidault, A, Dahan, L, Roquin, G, Aparicio, T, Legoux, J-L, Lombard-Bohas, C, Scoazec, J-Y, Lepage, C, Cadiot, G, CEPD investigators, Borbath, Ivan, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Walter, T, Tougeron, D, Baudin, E, Le Malicot, K, Lecomte, T, Malka, D, Hentic, O, Manfredi, S, Bonnet, I, Guimbaud, R, Coriat, R, Lepère, C, Desauw, C, Thirot-Bidault, A, Dahan, L, Roquin, G, Aparicio, T, Legoux, J-L, Lombard-Bohas, C, Scoazec, J-Y, Lepage, C, Cadiot, G, CEPD investigators, and Borbath, Ivan

Abstract

BACKGROUND: Diagnosis and management of poorly differentiated gastro-entero-pancreatic (GEP) neuroendocrine carcinomas (NECs) remain challenging. Recent studies suggest prognostic heterogeneity. We designed within the French Group of Endocrine Tumours a prospective cohort to gain insight in the prognostic stratification and treatment of GEP-NEC. PATIENTS AND METHODS: All patients with a diagnosis of GEP-NEC between 1st January 2010 and 31st December 2013 could be included in this national cohort. Adenoneuroendocrine tumours were excluded. RESULTS: 253 patients from 49 centres were included. Median age was 66 years. Main primary locations were pancreas (21%), colorectal (27%), oesophagus-stomach (18%); primary location was unknown in 20%. Tumours were metastatic at diagnosis in 78% of cases. Performance status (PS) at diagnosis was 0-1 in 79% of patients. Among the 147 (58%) cases reviewed by an expert pathological network, 39% were classified as small cell NEC and 61% as large cell NEC. Median Ki67 index was 75% (range, 20-100). Median overall survival was 15.6 (13.6-17.0) months. Significant adverse prognostic factors in univariate analysis were PS > 1 (hazard ratio [HR] = 2.5), metastatic disease (HR = 1.6), NSE>2 upper limit of normal [ULN]; HR = 3.2), CgA>2 ULN (HR = 1.7) and lactate dehydrogenase >2 ULN (HR = 2.1). After first-line palliative chemotherapy (CT1) with platinum-etoposide (n = 152), objective response, progression-free survival and overall survival were 50%, 6.2 and 11.6 months; they were 24%, 2.9 and 5.9, respectively, after post-CT1 FOLFIRI regimen (n = 72). CONCLUSIONS: We report a large prospective series of GEP-NEC which show the predominance of large cell type and advanced stage at diagnosis. Prognosis was found more homogeneous than previously reported, mainly impacted by PS and tumour burden.

Published
2017

44. Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension

Author

Cwikla, J.B., primary, Wolin, E.M., additional, Pavel, M., additional, Phan, A.T., additional, Raderer, M., additional, Sedláčková, E., additional, Cadiot, G., additional, Capdevila, J., additional, Rindi, G., additional, Lombard-Bohas, C., additional, Liyanage, N., additional, Truong Thanh, X-M., additional, Ruszniewski, P., additional, and Caplin, M., additional

Published
2017
Full Text
View/download PDF

45. Étude OPALINE : étude observationnelle en vie réelle, des traitements systémiques des tumeurs neuro-endocrines du pancréas (TNEp) non résécables ou métastatiques bien différenciées progressives

Author

Vicaut, E., primary, Smith, D., additional, Lombard-Bohas, C., additional, Dominguez, S., additional, Coriat, R., additional, Dubreuil, O., additional, Lecomte, T., additional, Santos, A., additional, Borie, O., additional, and Lepage, C., additional

Published
2017
Full Text
View/download PDF

46. Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog Therapy : Analysis of the Ongoing TELESTAR Extension Period

Author

Hrsch, D., Kulke, M., Caplin, M., Anthony, L., Bergsland, E., Öberg, Kjell, Welin, Staffan, Warner, R., Lombard-Bohas, C., Kunz, P., Valle, J., Fleming, D., Lapuerta, P., Banks, P., Pavel, M., Hrsch, D., Kulke, M., Caplin, M., Anthony, L., Bergsland, E., Öberg, Kjell, Welin, Staffan, Warner, R., Lombard-Bohas, C., Kunz, P., Valle, J., Fleming, D., Lapuerta, P., Banks, P., and Pavel, M.

Published
2016

47. Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study.

Author

UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Faivre, S, Niccoli, P, Castellano, D, Valle, J W, Hammel, P, Raoul, J-L, Vinik, A, Van Cutsem, E, Bang, Y-J, Lee, S-H, Borbath, Ivan, Lombard-Bohas, C, Metrakos, P, Smith, D, Chen, J-S, Ruszniewski, P, Seitz, J-F, Patyna, S, Lu, D R, Ishak, K J, Raymond, E, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Faivre, S, Niccoli, P, Castellano, D, Valle, J W, Hammel, P, Raoul, J-L, Vinik, A, Van Cutsem, E, Bang, Y-J, Lee, S-H, Borbath, Ivan, Lombard-Bohas, C, Metrakos, P, Smith, D, Chen, J-S, Ruszniewski, P, Seitz, J-F, Patyna, S, Lu, D R, Ishak, K J, and Raymond, E

Abstract

In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.

Published
2016

50. Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

Author

Horsch, D, primary, Kulke, M, additional, Caplin, M, additional, Anthony, L, additional, Bergsland, E, additional, Oberg, K, additional, Welin, S, additional, Warner, R, additional, Lombard-Bohas, C, additional, Kunz, P, additional, Valle, J, additional, Fleming, D, additional, Lapuerta, P, additional, Banks, P, additional, and Pavel, M, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results